Last reviewed · How we verify

Université NAZI BONI — Portfolio Competitive Intelligence Brief

Université NAZI BONI pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
premix insulin human isophane suspension and insulin human premix insulin human isophane suspension and insulin human marketed
Humulin N plus Humulin R Humulin N plus Humulin R marketed Insulin combination therapy Insulin receptor Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Eli Lilly and Company · 1 shared drug class
  2. Hospital Universitario San Ignacio · 1 shared drug class
  3. Peking University People's Hospital · 1 shared drug class
  4. Riverside University Health System Medical Center · 1 shared drug class
  5. Tehran University of Medical Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Université NAZI BONI:

Cite this brief

Drug Landscape (2026). Université NAZI BONI — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-nazi-boni. Accessed 2026-05-17.

Related